Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study
American Journal of Cancer Research · 2026 · 16 (6) · 2503-2517
DOI: 10.62347/dccq4239 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Qinghai Fu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sinopharm Dongfeng General Hospital Shiyan 442008, Hubei, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Sinopharm Dongfeng General Hospital Shiyan 442008, Hubei, China.
- Department of Gastrointestinal Surgery, Sinopharm Dongfeng General Hospital Shiyan 442008, Hubei, China.
Zitieren
APA
Fu, Q., Wang, X., Zheng, S., & Wang, W. (2026). Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study. American Journal of Cancer Research, 16(6), 2503-2517. https://doi.org/10.62347/dccq4239
Vancouver
Fu Q, Wang X, Zheng S, Wang W. Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study. American Journal of Cancer Research. 2026;16(6):2503-2517. doi:10.62347/dccq4239
BibTeX
@article{Fu2026,
author = {Fu, Qinghai and Wang, Xiaolong and Zheng, Shiqin and Wang, Wei},
title = {Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study},
journal = {American Journal of Cancer Research},
year = {2026},
volume = {16},
number = {6},
pages = {2503--2517},
doi = {10.62347/dccq4239}
}
EUVIMED